| Q37422775 | A Prospective, Randomized, Masked, Placebo-Controlled Clinical Study of Capromorelin in Dogs with Reduced Appetite |
| Q34055216 | Apo-Ghrelin Receptor (apo-GHSR1a) Regulates Dopamine Signaling in the Brain |
| Q46764801 | Associations of polymorphism within the GHSR gene with growth traits in Nanyang cattle |
| Q91649163 | Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males |
| Q38436118 | Capromorelin increases food consumption, body weight, growth hormone, and sustained insulin-like growth factor 1 concentrations when administered to healthy adult Beagle dogs |
| Q36241306 | Capromorelin oral solution (ENTYCE®) increases food consumption and body weight when administered for 4 consecutive days to healthy adult Beagle dogs in a randomized, masked, placebo controlled study. |
| Q50301613 | Capromorelin: a ghrelin receptor agonist and novel therapy for stimulation of appetite in dogs |
| Q96586975 | DETECTION OF BIOACTIVE PEPTIDES INCLUDING GONADOTROPHIN-RELEASING FACTORS (GnRHs) IN HORSE URINE USING ULTRA-HIGH PERFORMANCE LIQUID CHROMATOGRAPHY-HIGH RESOLUTION MASS SPECTROMETRY (UHPLC/HRMS) |
| Q37805634 | Doping and musculoskeletal system: short-term and long-lasting effects of doping agents |
| Q46349954 | Doping control analysis of seven bioactive peptides in horse plasma by liquid chromatography-mass spectrometry. |
| Q36576963 | Drug insight: The functions of ghrelin and its potential as a multitherapeutic hormone |
| Q37384321 | Dynamics of GHRH in third-ventricle cerebrospinal fluid of cattle: relationship with serum concentrations of GH and responses to appetite-regulating peptides. |
| Q42672818 | Effect of ghrelin on glucose-insulin homeostasis: therapeutic implications. |
| Q59806014 | Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats |
| Q51329685 | Effectiveness of GH isoform differential immunoassay for detecting rhGH doping on application of various growth factors. |
| Q30438239 | Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial |
| Q37854918 | Endocrine factors in the hypothalamic regulation of food intake in females: a review of the physiological roles and interactions of ghrelin, leptin, thyroid hormones, oestrogen and insulin. |
| Q48336588 | Evaluation of the safety in dogs of long-term, daily oral administration of capromorelin, a novel drug for stimulation of appetite |
| Q47732033 | Evaluation of the safety of daily administration of capromorelin in cats |
| Q30439746 | Evidence for acyl-ghrelin modulation of growth hormone release in the fed state |
| Q39712479 | GHRP-6 induces CREB phosphorylation and growth hormone secretion via a protein kinase Csigma-dependent pathway in GH3 cells |
| Q36700911 | Ghrelin and the central regulation of feeding and energy balance |
| Q36808343 | Ghrelin in the CNS: from hunger to a rewarding and memorable meal? |
| Q35970878 | Ghrelin promotes thymopoiesis during aging |
| Q27334682 | Ghrelin stimulation of growth hormone-releasing hormone neurons is direct in the arcuate nucleus |
| Q58326220 | Ghrelin, Lipid Metabolism, and Metabolic Syndrome |
| Q47098803 | Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. |
| Q93155751 | Growth Hormone Secretagogues and the Regulation of Calcium Signaling in Muscle |
| Q50902549 | Growth hormone treatment modulates active ghrelin levels in rats. |
| Q34181179 | Growth hormone-releasing hormone: not only a neurohormone. |
| Q36269981 | Growth hormone-releasing peptide-biotin conjugate stimulates myocytes differentiation through insulin-like growth factor-1 and collagen type I. |
| Q35532000 | Hunger states switch a flip-flop memory circuit via a synaptic AMPK-dependent positive feedback loop |
| Q35641980 | Identification of ghrelin receptor blocker, D-[Lys3] GHRP-6 as a CXCR4 receptor antagonist |
| Q42756416 | Influence of intravenous administration of growth hormone releasing peptide-2 (GHRP-2) on detection of growth hormone doping: growth hormone isoform profiles in Japanese male subjects |
| Q26852874 | Interrelationships between ghrelin, insulin and glucose homeostasis: Physiological relevance |
| Q34526408 | Modulation of the growth hormone-insulin-like growth factor (GH-IGF) axis by pharmaceutical, nutraceutical and environmental xenobiotics: an emerging role for xenobiotic-metabolizing enzymes and the transcription factors regulating their expression |
| Q36326745 | Non-lactational traits of importance in dairy cows and applications for emerging biotechnologies |
| Q30252874 | Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study |
| Q39174999 | Potassium Current Is Not Affected by Long-Term Exposure to Ghrelin or GHRP-6 in Somatotropes GC Cells |
| Q36729120 | Recent progress toward nonpeptide ligands for the melanocortin-4 receptor |
| Q34009312 | Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study |
| Q58099592 | Selective homodimerization of unprotected peptides using hybrid hydroxydimethylsilane derivatives |
| Q34574987 | Small molecule inhibitors of CXCR4. |
| Q54945060 | The CD36-PPARγ Pathway in Metabolic Disorders. |
| Q35567355 | The GHS-R blocker D-[Lys3] GHRP-6 serves as CCR5 chemokine receptor antagonist. |
| Q39235724 | The Safety and Efficacy of Growth Hormone Secretagogues |
| Q30426399 | The ghrelin axis in disease: potential therapeutic indications |
| Q81554535 | The growth hormone secretagogue receptor |
| Q30410009 | The role of ghrelin in GH secretion and GH disorders |
| Q40015267 | Up-regulation of high voltage-activated Ca(2+) channels in GC somatotropes after long-term exposure to ghrelin and growth hormone releasing peptide-6. |